FK506 Treatment of Noninfectious Uveitis

Ishioka, Misaki; Ohno, Shigeaki; Isobe, Kazumi; Watanabe, Nami; Ishigatsubo, Yoshiaki; Tanaka, Shun‐ichi

doi:10.1016/s0002-9394(14)72551-6

Cited by 88 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Azathioprine Eye involvement RCT [Yazici et al 1990] Retrospective study [Saadoun et al 2010] Vascular disease RCT [Yazici et al 1990] GI involvement Retrospective study Neuro-Behçet Case series [Kurtuncu et al 2008] Mycophenolate mofetil Neuro-Behçet Case series [Shugaiv et al 2011] Cyclosporine A Eye involvement RCTs [Ozyazgan et al 1992;Masuda et al 1989;BenEzra et al 1988] Open-label studies [Ermakova, 2003;Ozdal et al 2002;Fujino et al 1999;Sullu et al 1998;Whitcup et al 1994;Sajjadi et al 1994;Pacor et al 1994;Hayasaka et al 1994;Atmaca and Batioglu, 1994;Chavis et al 1992; [Mochizuki et al 1991[Mochizuki et al , 1992Ishioka et al 1994] Cyclophosphamide Vascular disease Retrospective studies [Hamuryudan et al 1994[Hamuryudan et al , 2004 Neuro-Behçet Retrospective study...…”

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

116

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Section: ]mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

116

101

View full text Add to dashboard Cite

show abstract

“…Whether tacrolimus, an immunosuppressive drug inhibiting immunophilins, might be beneficial for GO as it proved to be for other autoimmune disorders 45,46 , is conjectural.…”

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Novel Approaches to the Management of Graves` Ophthalmopathy

Bartalena

Tanda²,

Medea³

et al. 2002

View full text Add to dashboard Cite

Severe Graves' ophthalmopathy constitutes a complex therapeutic challenge and treatment outcome often is not satisfactory. Established methods of treatment include high-dose glucocorticoids, orbital radiotherapy and orbital decompression. Recently, the use of intravenous glucocorticoids has been shown to provide more favorable results than oral glucocorticoids. Novel treatments under investigation include somatostatin analogues, intravenous immunoglobulins and antioxidants. Low-dose immunosuppressive drugs (namely cyclosporine and, possibly, methotrexate) might be useful as an adjunct to established methods, particularly in view of a glucocorticoid-sparing action. Because cytokines play an important role in the pathogenesis of the disease, cytokine antagonists, which are currently evaluated in rheumatoid arthritis and other autoimmune conditions, might constitute in the future a valuable tool for the management of eye disease. Prevention of Graves' ophthalmopathy would be desirable, but so far it is limited to secondary prevention (arrest of progression of subclinical disease to clinical disease) and tertiary prevention (avoidance of deterioration or complications of clinical disease): among preventive measures smoking withdrawal is probably the most important one. Primary prevention (in the absence of disease) is only speculative, but oral tolerance induction or vaccination with the offending antigen(s) might prove beneficial for prevention of Graves' ophthalmopathy in genetically susceptible individuals.

show abstract

“…A number of clinical trials with FK506 have been processed throughout the world (17)(18)(19). Patients suffering from various uveitis diseases volunteered in these trials.…”

Section: Tacrolimusmentioning

confidence: 99%

“…Uveitis diseases, such as Behcet's disease, sympathetic ophthalmia, refractory uveitis (to corticosteroids and cyclosporin), idiopathic retinal vasculitis and sarcoidosis, were treated orally with 0.05 to 0.25 mg/kg FK506 (17)(18)(19)(20). Most uveitis symptoms were improved in a dose dependent manner with effective doses 0.1 mg/kg to 0.15 mg/kg (17). However, severe side effects, similar to those of cyclosporin A, were observed, especially in a higher dose regimen.…”

Section: Tacrolimusmentioning

confidence: 99%

Review: Uveitis and Immunosuppressive Drugs

Kulkarni

2001

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Uveitis, inflammation of the eye, is a common occurring disease resulting from a wide variety of traumatic and immunogenic insults and, in most cases, can be treated successfully by corticosteroids. However, corticosteroids have severe side effects. Alternative therapy is using nonsteroidal anti-inflammatory agents like indomethecin, diclofenac and flurbiprofen. The uveitic cases are prominent in the third world countries, and many of the patients are not responsive or become refractory to steroidal or nonsteroidal therapy. Therefore, there is another class of compounds "immunosuppressive drugs" found to be successful in treating uveitis. These include cyclosporin A, tacrolimus, and sirolimus. However, being immunosuppressive they also have side effects. Therefore, the effective therapy with lower side effects is the treatment with combination of these drugs in lower dosages. Cyclosporin A plus sirolimus or tacrolimus in threshold doses alleviate signs of uveitis with lower incidence of side effects.

show abstract

FK506 Treatment of Noninfectious Uveitis

Cited by 88 publications

References 10 publications

Update on the therapy of Behçet disease

Update on the therapy of Behçet disease

Novel Approaches to the Management of Graves` Ophthalmopathy

Review: Uveitis and Immunosuppressive Drugs

Contact Info

Product

Resources

About